Enzo Biochem (ENZ)
0.6531 -0.0049 (-0.74%) 01/24/25 [NYSE]
0.6203 x 1,300 1.3000 x 100
Realtime by (Cboe BZX)
0.6203 x 1,300 1.3000 x 100
Realtime 0.6444 -0.0087 (-) 01/24/25
for Fri, Jan 24th, 2025
Fiscal Year End Date: 07/31
(Values in U.S. thousands)
07-2024 | 04-2024 | 01-2024 | 10-2023 | 07-2023 | |
Cash Flows From Operating Activities | |||||
Net Income | -26,078 | -12,697 | -9,677 | -6,616 | 20,288 |
Depreciation Amortization | 1,272 | 874 | 537 | 270 | 2,682 |
Accounts receivable | 2,477 | 2,475 | 1,252 | 2,019 | 5,033 |
Accounts payable and accrued liabilities | -7,737 | -7,654 | -7,097 | -5,601 | 1,159 |
Other Working Capital | -8,254 | -16,693 | -15,267 | -9,510 | 18,558 |
Other Operating Activity | 12,061 | 8,521 | 7,940 | 6,064 | -84,696 |
Operating Cash Flow | $-26,259 | $-25,174 | $-22,312 | $-13,374 | $-36,976 |
Cash Flows From Investing Activities | |||||
PPE Investments | -545 | -422 | -279 | -254 | -2,760 |
Other Investing Activity | 0 | 0 | 0 | 0 | 101,740 |
Investing Cash Flow | $-545 | $-422 | $-279 | $-254 | $98,980 |
Cash Flows From Financing Activities | |||||
Change In Short Term Borrowing | N/A | N/A | N/A | N/A | 23,846 |
Debt Repayment | -110 | -110 | -73 | -51 | -4,136 |
Common Stock Issued | N/A | 0 | N/A | N/A | 400 |
Other Financing Activity | -4,083 | -474 | -467 | -467 | -21,235 |
Financing Cash Flow | $-4,193 | $-584 | $-540 | $-518 | $-1,125 |
Exchange Rate Effect | -5 | -37 | -1 | -20 | -109 |
Beginning Cash Position | 83,373 | 83,373 | 83,373 | 83,373 | 22,603 |
End Cash Position | 52,371 | 57,156 | 60,241 | 69,207 | 83,373 |
Net Cash Flow | $-31,002 | $-26,217 | $-23,132 | $-14,166 | $60,770 |
Free Cash Flow | |||||
Operating Cash Flow | -26,259 | -25,174 | -22,312 | -13,374 | -36,976 |
Capital Expenditure | -545 | -422 | -279 | -254 | -2,760 |
Free Cash Flow | -26,804 | -25,596 | -22,591 | -13,628 | -39,736 |